# US 5,350,571 A · Emulsions of highly fluorinated organic compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,350,571 A - Document ID: US5350571A - Status: Granted - Kind: A - Application number: 07/840,389 - Filed: 1992-02-24 - Granted: 1994-09-27 - Earliest claimed: 1988-04-29 - Assignees: HemaGen/PFC - Inventors: Robert J. Kaufman; Thomas J. Richard - Web page: https://patentgrep.com/patent/US5350571A ## CPC - A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender} - A61K 31/02: Halogenated hydrocarbons - Y10T 436/24: Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract Improved emulsions of highly fluorinated organic compounds. The emulsions comprise a highly fluorinated organic compound, an oil, that is not substantially surface active and not significantly water soluble, and a surfactant. They are characterized by a well-defined relationship in the relative amounts of the three components. ## Claims ### Claim 1 A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 400 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 400 nm after 5 days in serum or ionic solutions, (3) an LD.sub.50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 4.degree. c. ### Claim 2 A contrast agent for biological imaging comprising a physiologically acceptable emulsion in an amount clinically effective for imaging by modalities selected from the group consisting of nuclear magnetic resonance, x-ray, ultrasound and positron emission tomography, wherein the emulsion comprises a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly water soluble, and a surfactant, and wherein (a) the highly fluorinated organic compound is present in the emulsion in an amount between about 20% and about 60% by volume and (b) the amounts of the surfactant and oil in the emulsion are dependent on the volume percent of highly fluorinated organic compound and are present in amounts effective to produce emulsions characterized by (1) a particle size distribution of less than 300 nm after sterilization, (2) a serum stability characterized by a particle size distribution of less than 300 nm after 5 days in serum or ionic solutions, (3) an LD.sub.50 in rats of at least 16 ml/kg of the highly fluorinated organic compound component of the emulsion, (4) an at least 70% survival upon total exchange in rats, and (5) a shelf stability of at least several months at 25.degree. C. ### Claim 3 (depends on 1, 2) The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is present in the emulsion in an amount between about 30% and about 55% by volume. ### Claim 4 (depends on 1, 2) The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is present in the emulsion in about 40% by volume. ### Claim 5 (depends on 1, 2) The contrast agent according to claim 1 or 2, wherein the highly fluorinated organic compound is selected from the group consisting of perfluorooctylbromide and perfluorodecalin. ### Claim 6 (depends on 1, 2) The contrast agent according to claim 1 or 2, wherein the oil is selected from the group consisting of safflower oil and soybean oil. ### Claim 7 (depends on 1, 2) The contrast agent according to claim 1 or 2, wherein the surfactant is egg yolk lecithin. ### Claim 8 (depends on 1, 2) The contrast agent according to claim 1 or 2, further comprising at least one compound selected from the group consisting of isotonic agents, osmotic pressure controlling agents, serum extending agents and antioxidants. ### Claim 9 (depends on 1, 2) A method for non-invasive imaging of internal organs and bloodflow comprising the step of administering to a patient in a pharmaceutically acceptable manner a contrast agent selected from the contrast agents of claims 1 or 2 in conjunction with an imaging modality selected from magnetic resonance imaging, ultrasound, positron emission tomography and x-ray.